Stockreport

Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada

Theratechnologies Inc. - Common Shares  (THTX) 
PDF Addition of investigational RNA-targeted medicines build upon Theratechnologies’ foundational HIV portfolio Submissions to Health Canada planned for 2025 MONTREAL, Dec [Read more]